Synthetic Biologics

Rockville, United States Founded: 1986 • Age: 40 yrs
Developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases

About Synthetic Biologics

Synthetic Biologics is a Healthcare company based in Rockville (United States) founded in 1986. Developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The company has 21 employees. Its chief executive, as recorded, is Steven Shallcross. Synthetic Biologics offers products and services including Oncolytic Viruses, SYN-004, and VCN-01. Its focus areas include Life Sciences, Microbiome Therapeutics, Targeted Agents and Infectious Diseases. Its legal entity is SYNTHETIC BIOLOGICS, INC. Similar companies include Amyris, Kriya Therapeutics and Pivot Bio; 3 of its 3 listed similar companies have raised funding.

Company details

Founded in 1986 and headquartered in Rockville, United States, Synthetic Biologics operates as a clinical-stage company in the synthetic biology sector. Therapeutics are developed to safeguard the gut microbiome from intravenous beta-lactam antibiotics, aiming to prevent C. difficile infections and antibiotic-associated diarrhea through SYN-004. SYN-010 is advanced to address methane-producing organisms in IBS-C. Preclinical monoclonal antibodies for pertussis and biotherapeutics for phenylketonuria are pursued in collaboration with Intrexon Corporation.

  • Headquarters Rockville, United States
  • Employees 21
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website syntheticbiologics.com
  • Social LinkedIn X Facebook
  • Legal Name Synthetic Biologics, Inc.
Key Metrics
  • Annual Revenue
    $2.61 M (USD)
    as on Dec 31, 2010
  • Net Profit
    -$14.27 M (USD)
    -42
    as on Dec 31, 2021
  • EBITDA
    -$14.27 M (USD)
    -40
    as on Dec 31, 2021
  • Latest Funding Round
    $3M (USD), Post-IPO

    Jul 2022

  • Employee Count
    21

Products & Services of Synthetic Biologics

Synthetic Biologics offers a comprehensive portfolio of products and services, including Oncolytic Viruses, SYN-004, and VCN-01.

Oncolytic Viruses
Therapeutics

Engineered viruses to selectively destroy tumor cells.

SYN-004
Clinical Trial Drug

Targets protection in hematopoietic cell transplant recipients.

VCN-01
Oncology Treatment

Combines with chemotherapy for metastatic pancreatic cancer.

Funding Insights of Synthetic Biologics

  • Total Rounds 4
  • Last Round Post-IPO β€” $3M
  • First Round $10.8M

    (Nov 2012)

All 4 funding rounds of Synthetic Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2022$3MPost-IPO––
–
Sep 2017$12MPost-IPO––
–
Sep 2013$5.61MGrant––
–
Nov 2012$10.8MPost-IPO––
–

People of Synthetic Biologics

1 people are tracked at Synthetic Biologics (1 in leadership); the tracked headcount is 21.

NameRoleGroup
Steven Shallcross
CEOLeadership
Premium access

Complete people profiles for Synthetic Biologics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Synthetic Biologics

3 dated milestones of Synthetic Biologics across 36 years, from founding to its latest funding, stage changes and deals.

  1. Founded Synthetic Biologics is founded.
  2. Funding First funding round of $10.8M.
  3. Funding Latest funding round, Post-IPO, of $3.0M.

Similar companies to Synthetic Biologics

Synthetic Biologics has 3 listed similar companies in our database, 3 of them funded. They include Amyris, Kriya Therapeutics and Pivot Bio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
amyris.com2003Emeryville, United States$487.2M747
Developer of renewable products for industrial solutions
kriyatherapeutics.com2012Redwood, United States$930.93M159
Developer of therapeutic solutions for the treatment of diabetes
pivotbio.com2010Berkeley, United States$618.08M256
Nitrogen-fixing microbes for corn crop nutrition are developed and applied.
Premium access

Detailed similar companies of Synthetic Biologics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Synthetic Biologics

Websites that share an audience with Synthetic Biologics (syntheticbiologics.com).

Similar websites

Websites whose visitors overlap most with Synthetic Biologics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
tgtherapeutics.com
100%
29.4K#1,758,849View details
nacfconference.org
nacfconference.org
68%
#3,847,203–

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Synthetic Biologics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Synthetic Biologics

Premium access

Complete news archive for Synthetic Biologics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Synthetic Biologics

Synthetic Biologics was founded in 1986 and raised its 1st funding round 26 years after it was founded.

Synthetic Biologics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.

Steven Shallcross is the CEO of Synthetic Biologics, as recorded in our data.

Synthetic Biologics has 21 employees.

Annual revenue of Synthetic Biologics is $2.61M as on Dec 31, 2010.

Founded in 1986 and headquartered in Rockville, United States, Synthetic Biologics operates as a clinical-stage company in the synthetic biology sector. Therapeutics are developed to safeguard the gut microbiome from intravenous beta-lactam antibiotics, aiming to prevent C. difficile infections and antibiotic-associated diarrhea through SYN-004. SYN-010 is advanced to address methane-producing organisms in IBS-C. Preclinical monoclonal antibodies for pertussis and biotherapeutics for phenylketonuria are pursued in collaboration with Intrexon Corporation.

Synthetic Biologics's top competitors include Amyris, Pivot Bio and Kriya Therapeutics.

Synthetic Biologics offers Oncolytic Viruses, SYN-004, and VCN-01.

Synthetic Biologics operates through Synthetic Biologics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available